Cangene's Hepatitis B Therapeutic Approved in Canada for a Second Indication
News Apr 24, 2009
Cangene Corporation has reports that its HepaGam B® (Hepatitis B Immune Globulin (Human) Injection) has been approved by the Biologics and Genetic Therapies Directorate of Health Canada for treating acute exposure to hepatitis B virus. This is the second approved indication in Canada. HepaGam B® is a purified antibody or hyperimmune that is specific for hepatitis B virus.
Hepatitis B is a highly infectious virus that can be spread through contact with blood and other bodily fluids from an infected person or can be transmitted from an infected mother to a newborn during birth. HepaGam B® is also approved by the U.S. Food and Drug Administration (FDA) for this indication and for use in liver transplant recipients; HepaGam B® is the only hepatitis B immune globulin product approved for both these indications in North America.
"This approval is another good addition to our product line-up. It represents the culmination of a great deal of work by our clinical and regulatory teams. Data supporting this indication was collected from a very large study that was conducted largely in India; it was one of the largest clinical trial programs ever conducted there," said Dr. John Langstaff, Cangene's president and CEO. "This approval also allows us to market the product to a broader customer base," he said.
Specifically, this approval is for post-exposure prophylaxis use of HepaGam B®, i.e. for treatment of acute exposure to blood containing hepatitis B surface antigen (HBsAg), perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute hepatitis B infection.
Health Canada has granted a full Notice of Compliance (NOC) with no conditions for this use of the drug. A two-year-earlier Canadian approval (NOC/c) for use in liver transplant recipients, which made the drug available for those in need of the treatment, included the condition that the Company complete a confirmatory clinical study.
An NOC/c is granted to provide patients who are suffering from serious, life-threatening or severely debilitating illnesses or conditions, accelerated access to promising new therapies.
More and more consumers are using services like 23andMe to learn about their genetic blueprint. Included with most of these services is the ability for users to download their "raw" genetic data, which can be further analyzed using third-party apps. But little is known about how and why consumers are using these apps, or about a variety of potential risks associated with these apps, until now.READ MORE